.png)
Diabetic Retinopathy Market by Type and Management - Global Industry Analysis and Forecast to 2027
Published On : May 2022 Pages : 114 Category: Medical Devices Report Code : HC0622
SEGMENTS & REGIONS:
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Industry Trend Analysis
The global diabetic retinopathy market is projected to be around $2.6 billion by 2027. This growth can be attributed to increase in prevalence of diabetes, increase in demand for early screening techniques and increase awareness about disease and available treatments among patients. Increasing incidence of diabetes caused blindness will further enhance the growth of market during forecast period. As per International Diabetes Federation (IDF) 415 million people worldwide suffered from diabetes and diabetes related complications as of 2017 and this number is expected to reach 642 million by 2040. Diabetic retinopathy is characterized by neovascularization of retina, blurred vision and moderate to severe eye pain. This further leads to retinal detachment and complete loss of vision. Such high complications will lead to increase in demand for methods to treat diabetes retinopathy which will drive the market during forecast period However, dearth of skilled professionals and poor insurance facilities are restraining the market growth.
Type Outlook and Trend Analysis
Proliferative diabetic retinopathy segment dominated the global market in 2017. Proliferative diabetic retinopathy is a more advanced form of diseases characterized by gel like fluids that get deposited in the eye leading to blurring of vision. Thus if left untreated, can result in complete blindness.
Diabetic macular edema market is expected to witness high growth owing to rise in incidence of DME, rise in demand for technological advancements in ophthalmic surgery techniques, increasing geriatric population and increasing government initiatives to spread awareness about diabetes and its complications.
Treatment Outlook and Trends Analysis
Anti-VEGF segment held almost one-third share of the global market in 2017, owing to its property and features such as quick response and faster recovery time. Moreover, increasing number of proliferative diabetic diseases will further enhance the growth of this segment. Vitrectomy is poised to witness highest growth during forecast period, owing to rise in retinopathies prevalence and increasing elderly population requiring surgical treatments to treat PDR.
Regional Outlook and Trend Analysis:
U.S. accounted for more than three-fourth of the global market share in 2017. This large share can be attributed to various factors such as easy availability of drugs (such as Lucentis and Avastin) having anti-VEGF property, rise in awareness about diabetes and related disorders and increasing demand for early detection and diagnosis to prevent diabetes related loss of vision. Europe accounted for the second largest share owing to increase in adoption rate of advanced medical devices and increase in awareness among consumers especially in western countries. Japan dominated Asia-Pacific region due to large elderly population and highly sophisticated healthcare infrastructure. Emerging economies such as China, India and Brazil are expected to witness high growth due to presence of large elderly population base and increase in disposable income of people.
Competitive Insights
The global market is highly competitive in nature with the presence of both local and international players. Some of the major players are Bayer Healthcare, Novartis AG, Actavis PLC, ThromboGenics, Sirnaomics Incorporation, Genentech, Glycadia Pharmaceuticals, Regeneron Pharmaceuticals Inc., Alimera Sciences, Ampio Pharmaceuticals. These players are focusing on developing and commercializing advanced products to gain competitive advantage at global level. With many players entering in market, the market is expected to witness high growth during forecast period with cut-throat competition to acquire large market share.
Market Opportunities
Technological advancements will continue to play significant role in growth of the market. For instance, U.S. based Intelligent Retinal Imaging Systems has launched an integrated software diabetic retinopathy screening technique that not only enable early detection of disease but also enhances patients care.
Diabetic Retinopathy Market is segmented as follows –
By Type:
- Proliferative Diabetic Retinopathy
- Diabetic Macular Edema
By Management:
- Anti VEGF Drugs
- Steroid Implants
- Laser Surgeries
- Vitrectomy
By Region:
- North America
- U.S
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- Rest of the World
- Brazil
- South Africa
- Saudi Arabia
- Turkey
- United Arab Emirates
- Others
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2022 to 2027?
- What will be the industry market growth from 2022 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
- Diabetic Retinopathy Market, By Type, Estimates and Forecast, 2017-2027 ($Million)
- Diabetic Macular Edema
- Proliferative Diabetic Retinopathy
- Diabetic Retinopathy Market, By Management, Estimates and Forecast, 2017-2027 ($Million)
- Anti VEGF Drugs
- Steroid Implants
- Laser Surgeries
- Vitrectomy
- Diabetic Retinopathy Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
- North America
- North America Diabetic Retinopathy Market, By Type
- North America Diabetic Retinopathy Market, By Management
- U.S. Diabetic Retinopathy Market, By Type
- U.S. Diabetic Retinopathy Market, By Management
- Canada Diabetic Retinopathy Market, By Type
- Canada Diabetic Retinopathy Market, By Management
- Mexico Diabetic Retinopathy Market, By Type
- Mexico Diabetic Retinopathy Market, By Management
-
- Europe
-
- Europe Diabetic Retinopathy Market, By Country
- Europe Diabetic Retinopathy Market, By Type
- Europe Diabetic Retinopathy Market, By Management
-
- Germany Diabetic Retinopathy Market, By Type
- Germany Diabetic Retinopathy Market, By Management
- France Diabetic Retinopathy Market, By Type
- France Diabetic Retinopathy Market, By Management
- UK Diabetic Retinopathy Market, By Type
- UK Diabetic Retinopathy Market, By Management
- Italy Diabetic Retinopathy Market, By Type
- Italy Diabetic Retinopathy Market, By Management
- Spain Diabetic Retinopathy Market, By Type
- Spain Diabetic Retinopathy Market, By Management
- Rest of Europe Diabetic Retinopathy Market, By Type
- Rest of Europe Diabetic Retinopathy Market, By Management
-
- Asia-Pacific
- Asia-Pacific Diabetic Retinopathy Market, By Country
- Asia-Pacific Diabetic Retinopathy Market, By Type
- Asia-Pacific Diabetic Retinopathy Market, By Management
- Japan Diabetic Retinopathy Market, By Type
- Japan Diabetic Retinopathy Market, By Management
- China Diabetic Retinopathy Market, By Type
- China Diabetic Retinopathy Market, By Management
- Australia Diabetic Retinopathy Market, By Type
- Australia Diabetic Retinopathy Market, By Management
- India Diabetic Retinopathy Market, By Type
- India Diabetic Retinopathy Market, By Management
- South Korea Cell Culture Market, By Type
- South Korea Diabetic Retinopathy Market, By Management
- Rest of Asia-Pacific Diabetic Retinopathy Market, By Type
- Rest of Asia-Pacific Diabetic Retinopathy Market, By Management
-
- Rest of the World
- Rest of the World Diabetic Retinopathy Market, By Country
- Rest of the World Diabetic Retinopathy Market, By Type
- Rest of the World Diabetic Retinopathy Market, By Management
- Brazil Diabetic Retinopathy Market, By Type
- Brazil Diabetic Retinopathy Market, By Management
- South Africa Diabetic Retinopathy Market, By Type
- South Africa Diabetic Retinopathy Market, By Management
- Saudi Arabia Diabetic Retinopathy Market, By Type
- Saudi Arabia Diabetic Retinopathy Market, By Management
- Turkey Diabetic Retinopathy Market, By Type
- Turkey Diabetic Retinopathy Market, By Management
- United Arab Emirates Diabetic Retinopathy Market, By Type
- United Arab Emirates Diabetic Retinopathy Market, By Management
- Others Diabetic Retinopathy Market , By Type
- Others Diabetic Retinopathy Market, By Management
- Rest of the World
Table of Contents
1. Introduction
1.1. Report Description
1.2. Research Methodology
1.2.1. Secondary Research
1.2.2. Primary Research
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Share Analysis
3.3. Market Dynamics
3.3.1. Drivers
3.3.1.1. High Prevalence of Diabetes
3.3.1.2. Rise in Demand for Early Detection Techniques
3.3.1.3. Increased Awareness about Diabetes
3.3.2. Restraints
3.3.2.1. Dearth of Skilled Professionals
3.3.2.2. Poor Insurance Facilities
3.3.3. Opportunities
3.3.3.1. Emerging Market to Offer Lucrative Growth Opportunities
3.4. Industry Trends
4. Diabetic Retinopathy Market, By Type
4.1. Introduction
4.2. Diabetic Retinopathy Market Assessment and Forecast, By Type, 2017-2027
4.2.1. Proliferative Diabetic Retinopathy
4.2.1.1. Market Assessment and Forecast, By Region, 2017-2027 ($Million)
4.2.2. Diabetic Macular Edema
4.2.2.1. Market Assessment and Forecast, By Region, 2017-2027 ($Million)
5. Diabetic Retinopathy Market, By Management
5.1. Introduction
5.2. Diabetic Retinopathy Market Assessment and Forecast, By Management, 2017-2027
5.2.1. Anti VEGF Drugs
5.2.1.1. Market Assessment and Forecast, By Region, 2017-2027 ($Million)
5.2.2. Steroid Implants
5.2.2.1. Market Assessment and Forecast, By Region, 2017-2027 ($Million)
5.2.3. Laser Surgeries
5.2.3.1. Market Assessment and Forecast, By Region, 2017-2027 ($Million)
5.2.4. Vitrectomy
5.2.4.1. Market Assessment and Forecast, By Region, 2017-2027 ($Million)
6. Diabetic Retinopathy Market, By Region
6.1. Introduction
6.2. Diabetic Retinopathy Market Assessment and Forecast, By Region, 2017-2027 ($Million)
6.3. North America
6.3.1. Market Assessment and Forecast, By Country, 2017-2027 ($Million)
6.3.2. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.3.3. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
6.3.3.1. U.S.
6.3.3.1.1. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.3.3.1.2. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
6.3.3.2. Canada
6.3.3.2.1. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.3.3.2.2. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
6.3.3.3. Mexico
6.3.3.3.1. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.3.3.3.2. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
6.4. Europe
6.4.1. Market Assessment and Forecast, By Country, 2017-2027 ($Million)
6.4.2. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.4.3. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
6.4.3.1. Germany
6.4.3.1.1. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.4.3.1.2. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
6.4.3.2. France
6.4.3.2.1. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.4.3.2.2. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
6.4.3.3. UK
6.4.3.3.1. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.4.3.3.2. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
6.4.3.4. Italy
6.4.3.4.1. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.4.3.4.2. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
6.4.3.5. Spain
6.4.3.5.1. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.4.3.5.2. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
6.4.3.6. Russia
6.4.3.6.1. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.4.3.6.2. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
6.4.3.7. Rest of Europe
6.4.3.7.1. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.4.3.7.2. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
6.5. Asia-Pacific
6.5.1. Market Assessment and Forecast, By Country, 2017-2027 ($Million)
6.5.2. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.5.3. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
6.5.3.1. Japan
6.5.3.1.1. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.5.3.1.2. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
6.5.3.2. China
6.5.3.2.1. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.5.3.2.2. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
6.5.3.3. Australia
6.5.3.3.1. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.5.3.3.2. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
6.5.3.4. India
6.5.3.4.1. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.5.3.4.2. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
6.5.3.5. South Korea
6.5.3.5.1. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.5.3.5.2. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
6.5.3.6. Taiwan
6.5.3.6.1. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.5.3.6.2. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
6.5.3.7. Rest of Asia-Pacific
6.5.3.7.1. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.5.3.7.2. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
6.6. Rest of the World
6.6.1.1. Market Assessment and Forecast, By Country, 2017-2027 ($Million)
6.6.1.2. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.6.1.3. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
6.6.1.4. Brazil
6.6.1.4.1. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.6.1.4.2. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
6.6.1.5. Turkey
6.6.1.5.1. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.6.1.5.2. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
6.6.1.6. Saudi Arabia
6.6.1.6.1. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.6.1.6.2. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
6.6.1.7. South Africa
6.6.1.7.1. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.6.1.7.2. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
6.6.1.8. United Arab Emirates
6.6.1.8.1. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.6.1.8.2. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
6.6.1.9. Others
6.6.1.9.1. Market Assessment and Forecast, By Type, 2017-2027 ($Million)
6.6.1.9.2. Market Assessment and Forecast, By Management, 2017-2027 ($Million)
7. Company Profiles
7.1. Bayer Healthcare
7.1.1. Business Overview
7.1.2. Type Portfolio
7.1.3. Key Financials
7.1.4. Strategic Developments
7.2. Novartis AG
7.2.1. Business Overview
7.2.2. Type Portfolio
7.2.3. Key Financials
7.2.4. Strategic Developments
7.3. Regeneron Pharmaceuticals Inc.
7.3.1. Business Overview
7.3.2. Type Portfolio
7.3.3. Key Financials
7.3.4. Strategic Developments
7.4. Actavis PLC
7.4.1. Business Overview
7.4.2. Type Portfolio
7.4.3. Key Financials
7.4.4. Strategic Developments
7.5. ThromboGenics
7.5.1. Business Overview
7.5.2. Type Portfolio
7.5.3. Key Financials
7.5.4. Strategic Developments
7.6. Sirnaomics Incorporation
7.6.1. Business Overview
7.6.2. Type Portfolio
7.6.3. Key Financials
7.6.4. Strategic Developments
7.7. Genentech
7.7.1. Business Overview
7.7.2. Type Portfolio
7.7.3. Key Financials
7.7.4. Strategic Developments
7.8. Glycadia Pharmaceuticals
7.8.1. Business Overview
7.8.2. Type Portfolio
7.8.3. Key Financials
7.8.4. Strategic Developments
7.9. Alimera Sciences
7.9.1. Business Overview
7.9.2. Type Portfolio
7.9.3. Key Financials
7.9.4. Strategic Developments
7.10. Ampio Pharmaceuticals
7.10.1. Business Overview
7.10.2. Type Portfolio
7.10.3. Key Financials
7.10.4. Strategic Developments
List of Tables
Table 1.Global Diabetic Retinopathy Market, By Type ($Million), 2017-2025
Table 2.Proliferative Diabetic RetinopathyMarket, By Region ($Million), 2017-2025
Table 3.Diabetic Macular Edema Market, By Region ($Million), 2017-2025
Table 4.Global Diabetic Retinopathy Market, By Management ($Million), 2017-2025
Table 5.Anti VEGF Drugs Market, By Region ($Million), 2017-2025
Table 6.Steroid Implants Market, By Region ($Million), 2017-2025
Table 7.Laser Surgeries Market, By Application ($Million), 2017-2025
Table 8.Vitrectomy Market, By Region ($Million), 2017-2025
Table 9.NorthAmerica Diabetic Retinopathy Market, By Country, 2017-2025 ($Million)
Table10.North America Diabetic Retinopathy Market, By Type, 2017-2025 ($Million)
Table11.North America Diabetic Retinopathy Market, By Management, 2017-2025 ($Million)
Table12.U.S. Diabetic Retinopathy Market, By Type, 2017-2025 ($Million)
Table13.U.S. Diabetic Retinopathy Market, By Management, 2017-2025 ($Million)
Table 14.Canada Diabetic Retinopathy Market, ByType, 2017-2025 ($Million)
Table 15.Canada Diabetic Retinopathy Market, By Management, 2017-2025 ($Million)
Table16.Mexico Diabetic Retinopathy Market, By Type, 2017-2025 ($Million)
Table17.Mexico Diabetic Retinopathy Market, By Management, 2017-2025 ($Million)
Table18.Europe Diabetic Retinopathy Market, By Country, 2017-2025 ($Million)
Table19.Europe Diabetic Retinopathy Market, By Type, 2017-2025 ($Million)
Table20.Europe Diabetic Retinopathy Market, By Management, 2017-2025 ($Million))
Table21.Germany Diabetic Retinopathy Market, By Type, 2017-2025 ($Million)
Table 22.Germany Diabetic Retinopathy Market, By Management, 2017-2025 ($Million)
Table 23.France Diabetic Retinopathy Market, By Type, 2017-2025 ($Million)
Table 24.France Diabetic Retinopathy Market, By Management, 2017-2025 ($Million)
Table 25.UK Diabetic Retinopathy Market, By Type, 2017-2025 ($Million)
Table 26.UK Diabetic Retinopathy Market, By Management, 2017-2025 ($Million)
Table27.Italy Diabetic Retinopathy Market, By Type, 2017-2025 ($Million)
Table28.Italy Diabetic Retinopathy Market, By Management, 2017-2025 ($Million)
Table29.Spain Diabetic Retinopathy Market, By Type, 2017-2025 ($Million)
Table30.Spain Diabetic Retinopathy Market, By Management, 2017-2025 ($Million))
Table31.Russia Diabetic Retinopathy Market, By Type, 2017-2025 ($Million)
Table32.Russia Diabetic Retinopathy Market, By Management, 2017-2025 ($Million)
Table33.Rest of Europe Diabetic Retinopathy Market, By Type, 2017-2025 ($Million)
Table34.Rest of Europe Diabetic Retinopathy Market, By Management, 2017-2025 ($Million)
Table35.Asia-Pacific Diabetes Devices Market, By Country, 2017-2025 ($Million)
Table36.Asia-Pacific Diabetic Retinopathy Market, By Type, 2017-2025 ($Million)
Table37.Asia-Pacific Diabetic Retinopathy Market, ByManagement, 2017-2025 ($Million)
Table38.Japan Diabetic Retinopathy Market, By Type, 2017-2025 ($Million)
Table39.Japan Diabetic Retinopathy Market, By Management, 2017-2025 ($Million)
Table40.China Diabetic Retinopathy Market, By Type, 2017-2025 ($Million)
Table41.China Diabetic Retinopathy Market, By Management, 2017-2025 ($Million)
Table42.Australia Diabetic Retinopathy Market, By Type, 2017-2025 ($Million)
Table43.Australia Diabetic Retinopathy Market, By Management, 2017-2025 ($Million)
Table44.Australia Diabetic Retinopathy Market, By Application, 2017-2025 ($Million)
Table45.India Diabetic Retinopathy Market, By Type, 2017-2025 ($Million)
Table46.India Diabetic Retinopathy Market, By Management, 2017-2025 ($Million)
Table47.South Korea Diabetic Retinopathy Market, By Type, 2017-2025 ($Million)
Table48.South Korea Diabetic Retinopathy Market, By Management, 2017-2025 ($Million)
Table49.Taiwan Diabetic Retinopathy Market, By Type, 2017-2025 ($Million)
Table50.Taiwan Diabetic Retinopathy Market, By Management, 2017-2025 ($Million)
Table51.Rest of Asia-Pacific Diabetic Retinopathy Market, By Type, 2017-2025 ($Million)
Table52.Rest of Asia-Pacific Diabetic Retinopathy Market, By Management, 2017-2025 ($Million)
Table53.Rest of the World Diabetic Retinopathy Market, By Country, 2017-2025 ($Million)
Table54.Rest of the World Diabetic Retinopathy Market, By Type, 2017-2025 ($Million)
Table55.Rest of the World Diabetic Retinopathy Market, By Management, 2017-2025 ($Million)
Table56.Brazil Diabetic Retinopathy Market, By Type, 2017-2025 ($Million)
Table57.Brazil Diabetic Retinopathy Market, By Management, 2017-2025 ($Million)
Table58.Turkey Diabetic Retinopathy Market, By Type, 2017-2025 ($Million)
Table59.Turkey Diabetic Retinopathy Market, By Management, 2017-2025 ($Million)
Table60.Saudi Arabia Diabetic Retinopathy Market, By Type, 2017-2025 ($Million)
Table61.Saudi Arabia Diabetic Retinopathy Market, By Management, 2017-2025 ($Million)
Table62.South Africa Diabetic Retinopathy Market, By Type, 2017-2025 ($Million)
Table63.South Africa Diabetic Retinopathy Market, By Management, 2017-2025 ($Million)
Table64.United Arab Emirates Diabetic Retinopathy Market, By Type, 2017-2025 ($Million)
Table65.United Arab Emirates Diabetic Retinopathy Market, By Application, 2017-2025 ($Million)
Table66.Others Diabetic Retinopathy Market, By Type, 2017-2025 ($Million)
Table67.Others Diabetic Retinopathy Market, By Management, 2017-2025 ($Million)
Table68.Bayer Healthcare: Key Strategic Developments, 2017-2017
Table69.Novartis AG: Key Strategic Developments, 2017-2017
Table70.Regeneron Pharmaceuticals Inc.: Key Strategic Developments, 2017-2017
Table71.Actavis PLC: Key Strategic Developments, 2017-2017
Table72.ThromboGenics: Key Strategic Developments, 2017-2017
Table73.Sirnaomics Incorporation: Key Strategic Developments, 2017-2017
Table74.Genentech: Key Strategic Developments, 2017-2017
Table75.Glycadia Pharmaceuticals: Key Strategic Developments, 2017-2017
Table76.Alimera Sciences: Key Strategic Developments, 2017-2017
Table77.Ampio Pharmaceuticals: Key Strategic Developments, 2017-2017
List of Figures
Figure 1.Global Diabetic Retinopathy MarketShare, By Type, 2017 & 2025
Figure 2.Diabetic Retinopathy Market Share, By Management,2017 & 2025
Figure 4.Diabetic Retinopathy Market, By Region, 2017, ($Million)
Figure 5.Bayer Healthcare Net Revenues, 2017-2017 ($Million)
Figure 6.Bayer Healthcare Net Revenue Share, By Segment, 2017
Figure 7.Bayer Healthcare Net Revenue Share, By Geography, 2017
Figure 8.Novartis AG: Net Revenues, 2017-2017 ($Million)
Figure 9.Novartis AG: Net Revenue Share, By Segment, 2017
Figure 10.Novartis AG: Net Revenue Share, By Geography, 2017
Figure11.Regeneron Pharmaceuticals Inc.: Net Revenues, 2017-2017 ($Million)
Figure 12.Regeneron Pharmaceuticals Inc.: Net Revenue Share, By Segment, 2017
Figure13.Regeneron Pharmaceuticals Inc.: Net Revenue Share, By Geography, 2017
Figure 14.Actavis PLC: Net Revenues, 2017-2017 ($Million)
Figure 15.Actavis PLC: Net Revenue Share, By Segment, 2017
Figure16.Actavis PLC: Net Revenue Share, By Geography, 2017
Figure17.ThromboGenics: Net Revenues, 2017-2017 ($Million)
Figure18.ThromboGenics: Net Revenue Share, By Segment, 2017
Figure19.ThromboGenics: Net Revenue Share, By Geography, 2017
Figure20.Sirnaomics Incorporation: Net Revenues, 2017-2017 ($Million)
Figure 21.Sirnaomics Incorporation: Net Revenue Share, By Segment, 2017
Figure22.Sirnaomics Incorporation: Net Revenue Share, By Geography, 2017
Figure 23.Genentech: Net Revenues, 2017-2017 ($Million)
Figure24.Genentech: Net Revenue Share, By Segment, 2017
Figure25. Genentech: Net Revenue Share, By Geography, 2017
Figure26.Glycadia Pharmaceuticals.: Net Revenues, 2017-2017 ($Million)
Figure27.Glycadia Pharmaceuticals.: Net Revenue Share, By Segment, 2017
Figure28.Glycadia Pharmaceuticals: Net Revenue Share, By Geography, 2017
Figure 29.Alimera Sciences: Net Revenues, 2017-2017 ($Million)
Figure 30.Alimera Sciences: Net Revenue Share, By Segment, 2017
Figure 31.Alimera Sciences: Net Revenue Share, By Geography, 2017
Figure 32.Ampio Pharmaceuticals: Net Revenues, 2017-2017 ($Million)
Figure 33.Ampio Pharmaceuticals: Net Revenue Share, By Segment, 2017
Figure 34.Ampio Pharmaceuticals: Net Revenue Share, By Geography, 2017
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|